Why the study?
Does an implantable cardioverter defibrillator (ICD) reduce mortality or sudden cardiac death in patients at high risk?
Does an implantable cardioverter defibrillator (ICD) reduce mortality or sudden cardiac death in patients at high risk?
Answers are grounded in this paper and cite their sources.
ICDs are the most effective method for reducing the risk of sudden cardiac death in high-risk patients for both primary and secondary prevention.
It has been estimated that 180,000–450,000 people die suddenly in the US every year. Currently, the most effective method for reducing the risk of sudden death in those patients at highest risk is implantation of an internal cardioverter defibrillator (ICD). The evidence base for the benefit of the ICD has matured over the last two decades, and large studies have consistently shown reduced mortality or sudden cardiac death (SCD) in selected patient populations. Since its initial application in the early 1980s in patients who had already suffered an episode of SCD (secondary prevention), ICD use has expanded dramatically and now includes patients who are at high risk for a first event of SCD (primary prevention). More recent studies have focused on new technology, optimal programming, and other gaps in our understanding of the use of ICDs.
No takes yet. Share an insight, caveat, or question.
Kusumoto et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: